Explore

Rapid ReadRapid Read
Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform

Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform

Sensible Biotechnologies, a company focused on developing naturally modified mRNA medicines, has secured $47 million in financing. This funding includes a Series A round led by Oxford Science Enterprises and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. The investment will support the advancement and scaling of Sensible's integrated mRNA technology, specifically its VECTOR™ platform. This platform aims to overcome limitations of conventional synthetic mRNA production by using living cells to produce naturally modified mRNA. The company's approach is designed to reduce immunogenicity, achieve high protein expression, and avoid double-stranded RNA (dsRNA) contamination, a common issue with synthetic mRNA. Sensible Biotechnologies plans to use this financing to scale up its VECTOR platform, expand its AI-enabled mRNA design and high-throughput screening capabilities, and develop clinical-grade manufacturing capabilities.
TrendlineTrendline
Gilead Sciences Expands AI-Enabled DevOps Capabilities with Cognizant Partnership Extension

Gilead Sciences Expands AI-Enabled DevOps Capabilities with Cognizant Partnership Extension

Gilead Sciences Expands AI-Enabled DevOps Capabilities with Cognizant Partnership Extension
TrendlineTrendline
Zeta Global CEO David Steinberg Discusses AI Strategy and Data Usage

Zeta Global CEO David Steinberg Discusses AI Strategy and Data Usage

Zeta Global CEO David Steinberg Discusses AI Strategy and Data Usage
Rapid ReadRapid Read
AI Bias Mitigation Efforts May Reduce Model Confidence Rather Than Correcting Underlying Preferences

AI Bias Mitigation Efforts May Reduce Model Confidence Rather Than Correcting Underlying Preferences

Research indicates that current methods for mitigating bias in large language models (LLMs), particularly activation steering, may not be effectively correcting the models' underlying biases. Instead, these methods appear to reduce the models' confidence, leading to an increased tendency to abstain from answering or to provide more generalized, less specific responses. This effect is observed across various LLMs, including Llama-3.1-8B, Falcon3-7B, Qwen3.5-9B, and Ministral-3-8B. When models are given an option to abstain, steering towards debiasing directions significantly increases the probability of choosing the abstain option. In scenarios where abstention is not an option, the steering leads to an equilibration of answer probabilities, increasing entropy and decreasing overall confidence. This suggests that the debiasing directions identified in latent space are highly aligned with model confidence rather than solely targeting and correcting biased preferences.
Rapid ReadRapid Read
AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

Artificial intelligence is revolutionizing clinical trials by significantly improving the speed, standardization, and objectivity of medical imaging analysis. Traditionally, radiologists manually review images like MRI, CT, and PET scans, a process that is time-consuming and prone to variability. AI-driven tools, utilizing deep learning and computer vision, can detect subtle changes in disease progression that are often difficult for humans to quantify. This advancement is leading to faster decision-making in drug development, with industry reports indicating AI can accelerate imaging review timelines by up to 50%. Regulatory agencies are increasingly receptive to AI in clinical trials, provided the tools are properly validated, as AI provides clear, quantifiable evidence crucial for submissions. Beyond imaging, AI is also being used to broaden clinical trial screening and is integrated into adaptive clinical trial designs. The FDA has established the Office of Innovation and Clinical Trial Modernization t...
TrendlineTrendline
Multiply Labs Secures $75 Million to Automate Drug Manufacturing

Multiply Labs Secures $75 Million to Automate Drug Manufacturing

Multiply Labs Secures $75 Million to Automate Drug Manufacturing
ReutersReuters
Existential threats join bubble fears as AI mood sobers at Singapore forums

Existential threats join bubble fears as AI mood sobers at Singapore forums

By Ankur Banerjee SINGAPORE, Oct 7 (Reuters) - Existential and financial risks posed by the artificial intelligence boom were top of mind for investors and policymakers at two conferences in Singapore on Wednesday, highlighting a cautious shift in mood around the AI trade.
TrendlineTrendline
Shanghai Biotech Sector Challenges U.S. Dominance in Drug Development

Shanghai Biotech Sector Challenges U.S. Dominance in Drug Development

Shanghai Biotech Sector Challenges U.S. Dominance in Drug Development
TrendlineTrendline
10x Genomics Seeks Senior Program Manager for R in Pleasanton

10x Genomics Seeks Senior Program Manager for R in Pleasanton

10x Genomics Seeks Senior Program Manager for R in Pleasanton
ReutersReuters
AstraZeneca to invest over $1 billion in Massachusetts, boost workforce

AstraZeneca to invest over $1 billion in Massachusetts, boost workforce

Oct 5 (Reuters) - AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 billion US investment plan, a move expected to expand its workforce in the state by more than 50% in the coming years.
TrendlineTrendline
Japan Aims to Boost Pharmaceutical Industry Growth to G7 Average, Focuses on AI-Enabled Drug Discovery

Japan Aims to Boost Pharmaceutical Industry Growth to G7 Average, Focuses on AI-Enabled Drug Discovery

Japan Aims to Boost Pharmaceutical Industry Growth to G7 Average, Focuses on AI-Enabled Drug Discovery
Rapid ReadRapid Read
HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

The U.S. Department of Health and Human Services (HHS) has announced a new program and three complementary projects aimed at significantly speeding up clinical trials through the integration of artificial intelligence (AI), advanced computational models, and real-time analysis. The core initiative, named SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials), seeks to develop AI-powered platforms that will continuously and adaptively support clinical trial designs. This program includes the creation of a phaseless design engine to simulate trials for faster results with fewer patients, a continuous inference engine for real-time data analysis and trial adaptations, and an agentic AI operations layer to automate startup activities and data collection. These efforts are part of a broader strategy by HHS to transform U.S. clinical trials, building on previous initiatives like Operation TrialBlazer and the FDA's pilot program using AI for real-time clinical trial data monitoring. The goal ...